history

[키워드] 1:1 acute respiratory syndrome Adverse drug reaction Adverse drug reactions alcohol All study participants allergy allocation sequence Alpha anticipated Antiviral Arm ARMS assigned Bandar Abbas blinded Blinding block randomization Breastfeeding C-reactive protein Chain Reaction chronic hepatitis cirrhosis clinical clinical symptom Clinical symptoms clinical trials Clinicians Computed tomography conducted Confirmed Control control group Corticosteroids COVID-19 COVID-19 pneumonia criteria Critical Department Depression diabetes Diabetes Mellitus Diagnosis Diseases dissemination dose double-blind drug drugs education Efficacy and safety element evaluate exclusion criteria faculty feature generate Hepatitis history Hospitalization Hospitalized hypertension IL-1β IL-6 ill patient IMPROVE incidence inclusion criteria inflammatory parameter inflammatory parameters Inflammatory responses Informed consent interleukin interleukin-1β Iran liver diseases Medical Sciences Medicines melatonin Ministry of Health number Nurses objective outcome oxygen oxygen saturation parallel-group participant Participants Patient patients patients randomized pharmaceutical Pharmacy Placebo placebo-controlled clinical trial Pneumonia polymerase chain polymerase chain reaction polymerase chain reaction) positive Pregnancy Primary outcome Primary outcomes protocol random randomization Randomized Randomized controlled trial regimen Registered registration date registration number registry Research respiratory Sample size SARS-CoV-2 screened secondary outcome Secondary outcomes Seizure serum Seven Severe acute respiratory syndrome single-center standard treatment status Study protocol the Faculty therapeutic treatment arm trial protocol Trial registration Tumor tumor necrosis tumor necrosis factor tumor necrosis factor-alpha two group two groups underlying diseases university Version Warfarin web-based system website X-ray
[DOI] 10.1186/s13063-020-04737-w PMC 바로가기 [Article Type] Letter